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Abstract
Background: Rab11 and its effector molecule, Rab11-FIP3 (FIP3), associate with recycling endosomes and traffic
into the furrow and midbody of cells during cytokinesis. FIP3 also controls recycling endosome distribution during
interphase. Here, we examine whether phosphorylation of FIP3 is involved in these activities.
Results: We identify four sites of phosphorylation of FIP3 in vivo, S-102, S-280, S-347 and S-450 and identify S-102
as a target for Cdk1-cyclin B in vitro. Of these, we show that S-102 is phosphorylated in metaphase and is
dephosphorylated as cells enter telophase. Over-expression of FIP3-S102D increased the frequency of binucleate
cells consistent with a role for this phospho-acceptor site in cytokinesis. Mutation of S-280, S-347 or S-450 or other
previously identified phospho-acceptor sites (S-488, S-538, S-647 and S-648) was without effect on binucleate cell
formation and did not modulate the distribution of FIP3 during the cell cycle. In an attempt to identify a functional
role for FIP3 phosphorylation, we report that the change in FIP3 distribution from cytosolic to membrane-
associated observed during progression from anaphase to telophase is accompanied by a concomitant
dephosphorylation of FIP3. However, the phospho-acceptor sites identified here did not control this change in
distribution.
Conclusions: Our data thus identify FIP3 as a cell cycle regulated phosphoprotein and suggest dephosphorylation
of FIP3 accompanies its translocation from the cytosol to membranes during telophase. S102 is dephosphorylated
during telophase; mutation of S102 exerts a modest effect on cytokinesis. Finally, we show that de/phosphorylation
of the phospho-acceptor sites identified here (S-102, S-280, S-347 and S-450) is not required for the spatial control
of recycling endosome distribution or function.
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Background
Membrane traffic to the furrow is an essential facet of
cytokinesis [1-5]. The plasma membrane of the furrow
of dividing cells has a distinct lipid and protein compo-
sition as compared to the rest of the plasma membrane,
with the furrow enriched in cholesterol and phosphati-
dylinositol 4, 5-bisphosphate (for example) and various
proteins involved in intracellular membrane trafficking
(e.g. dynamin, SNAREs, etc.) [2,5,6]. Exocytosis of intra-
cellular membranes occurs to the furrow and intercellu-
lar bridge, reflecting a requirement for the delivery of
intracellular signalling and/or membrane re-modelling
activities to the correct spatial co-ordinates during
abscission [1-4]. Identifying the molecular basis of these
trafficking events is crucial for a full understanding of
cell division.
We previously have shown that Rab11 and its effector
molecule, Rab11-FIP3 (FIP3), associate with recycling
endosomes and traffic into the furrow and midbody
[7,8]. Depletion of FIP3 or expression of a FIP3 mutant
unable to bind Rab11 results in defective abscission, and
both these genes are over-expressed in cancer [5]. FIP3
can bind both Rab11 and Arf6 GTPases simultaneously,
and FIP3, Rab11 and Arf6 form a ternary complex
in vitro [9], prompting us to suggest that multiple inter-
actions between Rab11 and Arf6 with the Exocyst
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the midbody prior to abscission [9], where they function
as an organisation platform for the assembly of the
abscission machinery [10]. Recent studies have also sug-
gested that a dynamic interaction of FIP3 with the cen-
tralspindlin component Cyk-4 may also contribute to
the localisation of FIP3 during mitosis [11]. FIP3 exhi-
bits profound spatial and temporal dynamics during cell
division [8,9]. GFP-FIP3 redistributes from diffuse cyto-
solic staining onto membranes at the centrosome during
early anaphase; GFP-FIP3 then begins to accumulate in
the developing furrow before entering the midbody and
at very late telophase accumulating at or close to the
midbody ring. Similar distributions have recently been
reported for endogenous FIP3 [12]. In addition to its
role in mitosis, FIP3 has also been suggested to control
the spatial distribution of recycling endosomes in inter-
phase cells [7,13], raising the question of how these dis-
tinct functions are modulated. Recent work has revealed
that FIP3 is a phospho-protein with multiple phospho-
acceptor sites [14]. Phosphorylation of residues S-488,
S-538, S-647 and S-648 modulates the interaction of
FIP3 with motor machinery, thereby controlling the spa-
tial distribution of endosomes [14]. However, there is no
published work relating phosphorylation of FIP3 at
these or other sites to events in the cell cycle.
H e r e ,w ei d e n t i f ya n dc h a r a c t e r i s ef o u rs i t e so fF I P 3
phosphorylation: S-102, S-280, S-347 and S-450. We
show that Cdk1, which is active in metaphase [15-17],
phosphorylates FIP3 exclusively on S-102 in vitro,a n d
that S-102 phosphorylation of FIP3 declines in parallel
with cyclin B levels as cells exit metaphase and proceed
into telophase. A phospho-mimetic mutation of this site
(S102D) exerted a modest effect on cytokinesis. Indivi-
dual mutants at S-280, S-347 and S-450 or a mutant of
FIP3 in which S-488, S-538, S-647 and S-648 were all
mutated to alanine had no effect on cytokinesis and did
not modulate FIP3 distribution during the cell cycle. We
further show that FIP3 is a cell cycle-regulated phospho-
protein and show that the shift in FIP3 distribution from
membranes to cytosol occurs concomitantly with depho-
sphorylation of FIP3, but that dephosphorylation of FIP3
alone is insufficient to promote membrane association in
vitro. Of the sites identified here, we show that S102 is
dephosphorylated as cells move from metaphase into tel-
ophase. Finally, we show that phospho-mimetic or phos-
pho-resistant mutants of S-102, S-280, S-347 or S-450 do
not modulate transferrin uptake or recycling endosome
distribution in interphase cells.
Results
GFP-tagged FIP3 undergoes a re-distribution from a dif-
fuse cytosolic distribution to membrane compartment
centred over the centrosome as cells progress from
metaphase to anaphase [8]. During early telophase,
GFP-FIP3 accumulates near DNA but at the opposite
side of the centrosomes, before gradually moving to
mid-zone microtubules and then eventually translocat-
i n gi n t ot h em i d b o d yi nl a t et e l o p h a s e ,j u s tp r i o rt o
abscission [8,11]. A similar pattern has recently been
reported for endogenous FIP3 [12]. We performed a
simple subcellular fractionation of HeLa cell homoge-
n a t e si s o l a t e da tp r o p h a s e / metaphase or telophase and
studied the distribution of the endogenous protein
between membrane and cytosolic fractions (Figure 1A,
B). FIP3 was found to re-distribute from the cytosol to
membrane fractions in telophase, consistent with pre-
vious imaging studies [7-9,12].
Previous studies have suggested that FIP3 is a phos-
phoprotein, with over 20 sites of phosphorylation identi-
fied [14]. We hypothesised that phosphorylation/
dephosphorylation may represent a potential mechanism
for this regulation of FIP3 localisation or function. We
immunoprecipitated FIP3 from HeLa cells arrested in
metaphase, and examined the distribution of FIP3 on
2D-gel electrophoresis by immunoblotting and com-
pared the signal to that obtained from identical samples
treated with alkaline phosphatase (Figure 2A). Phospha-
tase treatment consistently reduced the number of FIP3-
immunoreactive species identified, consistent with the
notion that FIP3 is phosphorylated in metaphase. We
identified four phospho-peptides by mass spectrometry
(Figure 2B), which encompassed S102, S280, S347 and
S450 (Figure 2C). Although not all of these sites were
observed in the previous study [14], it should be noted
that we have focussed our study on FIP3 in metaphase.
FIP3 is phosphorylated by Cdk1 in vitro on S102
We next generated a phospho-selective antibody to detect
phosphorylation of residue S102. This reagent readily
detected recombinant FIP3 purified from Baculovirus, and
also recombinant FIP3 phosphorylated on S102 by incuba-
tion with Cdk1-cyclin B (see below); the signal was selec-
tively blocked by the phosphorylated antigenic peptide,
but not the corresponding non-phosphorylated control
peptide (Figure 3A). This antibody also readily detected
phosphorylation of S102 within the context of GFP-FIP3
ectopically expressed in HeLa cells (note that expression
of endogenous FIP3 is low, and below the limits of detec-
tion with this reagent) (Figure 3B). We found that total
levels of phosphorylation of S102 within GFP-FIP3
decreased as cells progressed from metaphase (~30 min)
to telophase (~120 min; cf. cyclin B immunoblot) but total
cellular levels of GFP-FIP3 (detected with anti-GFP anti-
bodies) were unchanged (Figure 3C, D). Phospho-FIP3
could be detected only within the cytosolic pool of FIP3,
and levels of phosphorylation declined markedly as cells
progressed from metaphase to telophase (Figure 3C, D).
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Page 2 of 15S102 is within in a consensus sequence similar to that
for Proline-directed kinases, such as cyclin-dependent
kinase 1 (Cdk1). Consistent with this, Figure 4 shows
that recombinant Cdk1-cyclin B readily phosphorylates
Baculovirus expressed recombinant FIP3. Mass spectro-
metry revealed that Cdk1 had phosphorylated recombi-
nant FIP3 only on residue S102 (data not shown, but see
also Figure 3A). We also performed in vitro kinase assays
with Plk1, Aurora A and Aurora B; no specific phosphor-
ylation events could be identified (LLC and GWG,
unpublished data). Attempts to generate phospho-speci-
fic antibodies to the other sites identified in Figure 2
have thus far proven unsuccessful. Hence, we cannot
ascertain whether phosphorylation of S280, S347 or S450
is cell cycle-dependent (but see further below).
Consequences of FIP3 phosphorylation
In an attempt to determine the role of phosphorylation of
FIP3 at these sites, we generated a panel of either S > A
or S > D mutants within the context of GFP-FIP3.
Expression of these mutants in HeLa cells (with the
exception of S450A - see Discussion) did not affect cell
growth (data not shown). We next examined whether
over-expression of these mutants gave rise to defective
cytokinesis by counting binuclear cells. A modest
increase in the fraction of binuclear cells was observed in
cells expressing GFP-FIP3-S102D. However, this effect
was smaller than was observed in cells expressing GFP-
FIP3-I737E, a Rab11-binding deficient mutant of FIP3,
previously shown to increase the number of binuclear
cells [8] despite similar levels of expression of these
mutants (Figure 5A, B). Similarly, the membrane/cytosol
distribution of GFP-FIP3-S102D revealed a modest
decrease in ratio in metaphase compared to GFP-FIP3-
S102A or GFP-FIP3 (Figure 5C; compare to Figure 1A).
Such data support the possibility that de/phosphorylation
of S102 is involved in cell division. Surprisingly, when
expressed in HeLa cells as GFP-fusion proteins, the dis-
tribution of the individual S > A or S > D mutants of
FIP3 appeared indistinguishable from wild-type FIP3
throughout the stages of the cell cycle. Figure 5D shows
the localisation in early and late telophase for GFP-
S102A and GFP-S102D. Similar results were observed
when all other mutants were expressed (data not shown).
Phosphorylation of ser-488, 538, 647 and 648 is not
required for cytokinesis
Recent studies have identified more than 20 phospho-
acceptor sites on FIP3 and its fly homologue Nuclear
Fallout (Nuf) [14]. Mutation of four phospho-acceptor
s i t e sw i t h i nF I P 3t oA l a n i n e( S e r - 4 8 8 ,5 3 8 ,6 4 7a n d6 4 8 ;
HA-FIP3-4[A] - see Figure 2C) was also shown to modu-
late recycling endosome directionality, perhaps by regu-
lating the interaction of FIP3 with dynein [14]. Since we
and others have proposed that the accumulation of FIP3-
containing vesicles in the midbody is a crucial facet of
cytokinesis [6,18], we posited that the de/phosphorylation
of FIP3 at these sites may control the interaction of FIP3-
positive vesicles with the microtubule network and thus
the distribution of FIP3 in the cell cycle. However, over-
Figure 1 FIP3 translocates from cytosol to membranes during the cell cycle Panels A and B. Synchronized HeLa cells were harvested at
different time points after release from the nocodazole block as shown. Cells were fractionated into cytosolic and membrane fractions and
levels of FIP3 analyzed by immunoblotting, with 60 μg of each fraction loaded in each lane. Data shown in panel A are the means and
standard deviations from three independent experiments. In panel B, “prophase/metaphase” represents samples harvested at 0 min after release
from nocodazole block, while “telophase” represents samples harvested 70 min after release from nocodazole block. Transferrin Receptor (TfR)
was used as a marker for membranes, and RCP/FIP1 as an unrelated FIP for comparative purposes.
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Page 3 of 15Figure 2 Identification of putative FIP3 phosphorylation sites Panel A.S y n c h r o n i z e dH e L ac e l l sf r o mm e t a p h a s ew e r el y s e da n dF I P 3
immuno-precipitated (from untreated or phosphatase-treated lysates) using anti-FIP3 antibodies. Immunoprecipitates were then separated by 2D
SDS-Page and immunoblotted with anti-FIP3 antibodies. Asterisks mark different phospho-states of FIP3. A representative blot is shown for each
condition. Panel B. Synchronized HeLa cells in metaphase were lysed in the presence of phosphatase inhibitors. FIP3 was then precipitated and
putative phosphorylation site identified by mass spectrometry. Shown are all the peptides identified for each putative phosphorylation site.
Panel C. A schematic of FIP3 showing the location of key residues. Phospho-acceptor sites identified here are shown in blue, those in black at
the sites mutated to A in the HA-FIP3-4A mutant (see text). The Rab11-binding region (RBD) and Arf6 interaction region (ABD) are shown,
together with the approximate position of the EF-hand-like domains and the coiled-coil region.
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Page 4 of 15Figure 3 FIP3 is phosphorylated on S102 in a cell cycle-dependent manner. Panel A 200 ng of His6-tagged recombinant FIP3, or 200 ng
His6-tagged recombinant FIP3 incubated with Cdk1-cyclin B to phosphorylate the protein on S102 (see below) were separated by SDS-PAGE,
transferred to nitrocellulose and analysed by immunoblotting using 0.2 μg/ml affinity-purified anti-pS102 antibodies, incubated in the presence
of either the phosphorylated or non-phosphorylated peptide (2.5 μM) as indicated. The position of molecular weight markers (kDa) is shown.
Data from a typical experiment are presented, repeated four times with similar results. Panel B HeLa cells expressing GFP-FIP3 (or control cells)
were lysed as described in Methods. Samples of lysate were separated by SDS-PAGE, transferred to nitrocellulose and probed with anti-pS102
antibodies. GFP-FIP3 is readily detected (endogenous FIP3 is expressed at too low levels to be readily detected by this antibody). Panel C HeLa
cells stably expressing GFP-FIP3 were synchronised using a thymidine and nocodazole block as described in Methods. Cells were harvested 30,
60, 90 or 120 min after release from the block, corresponding to metaphase (~30 min) through late telophase (120 min)[11], fractionated into
membrane and cytosolic fractions, and these fractions together with the initial homogenate (total) were immunoblotted with anti-GFP (to reveal
total GFP-FIP3 levels in each fraction), anti-pS102 and anti-cyclin B as shown. Data from a typical experiment is presented, repeated three times
with quantitatively similar results, which are quantified in Panel D (the signals at each point and in each fraction are expressed as a% of that in
the 30 minute total cell lysate level. The mean of triplicate experiments (± S.D.) is shown).
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Page 5 of 15expression of HA-FIP3 (wild-type) and HA-FIP3-[4A]
revealed that the 4A mutant did not affect cytokinesis, as
revealed by quantification of the levels of binucleate cells
(Additional file 1: Figure S1). The membrane/cytosol
ratio of HA-FIP3 (wild-type) and HA-FIP3-[4A] in meta-
phase were similar (data not shown), consistent with
these mutations not exerting a significant effect on the
interaction of FIP3 with membranes in metaphase. Simi-
larly, the cell cycle distribution of HA-FIP3-4A was indis-
tinguishable from wild-type HA-FIP3 (Figure 5E). It will
be necessary to examine the distribution of the corre-
sponding Aspartate mutants to definitely rule out a role
for phosphorylation/dephosphorylation of these residues,
but the Alanine mutant employed here strongly suggests
that phosphorylation/dephosphorylation of these sites
may not play a crucial role in cytokinesis.
Phosphorylation of FIP3 does not modulate GFP-FIP3
distribution or recycling endosome function in
interphase cells
The functional role of FIP3 is not confined to events in
the cell cycle, but studies have revealed an important role
for FIP3 in the control of recycling endosome distribu-
tion and function [8,13,19]. Previous studies have sug-
gested that expression of GFP-FIP3 results in a clustering
of FIP3 into a peri-nuclear region, concomitant with a
clustering of recycling endosomes [7,19]. Expression of
these mutant FIP3 species reveal that this clustering is
unaffected by either the phospho-mimetic (S > D; Figure
6) or phospho-resistant mutations (not shown). This is in
marked contrast to expression of GFP-FIP3-I737E, a
Rab11-binding deficient mutant, which is predominantly
cytosolic, consistent with a role for Rab11 in the recruit-
ment of FIP3 to membranes [7,8]. Consistent with this,
analysis of the uptake of fluorescently labelled transferrin
revealed significant accumulation of label into the clus-
tered GFP-FIP3 compartment, and that the correspond-
ing S > D (Figure 6) and S > A (data not shown) mutants
were without effect on transferrin accumulation. The
data shown in Figure 6 are from cells exposed to labelled
transferrin for 30 minutes; analysis of earlier time points
(5 minutes) revealed no difference in accumulation
between wild-type and phospho-mutants of FIP3 (data
not shown). Thus, the phospho-acceptor sites identified
here do not appear to modulate either the clustering of
recycling endosomes induced by FIP3 over-expression, or
the ability of cargo to traffic into these endosomes. Simi-
lar data has been reported for the HA-FIP3-[4A] mutant
[14].
FIP3 is a cell cycle-regulated phospho-protein
The data presented above suggest that the phospho-
acceptor sites identified here (S-102, S-280, S-347 and S-
450) play at best a minimal role in the control of FIP3
Figure 4 Cdk1-cyclin B phosphorylates FIP3 on S102. Recombinant FIP3 was expressed as a His6-fusion protein in Sf9 cells and purified as
described in Methods. The left panel shows a protein stain of 2 and 5 μg of purified FIP3 with the position of molecular weight markers indicated
(kDa). 0, 2 and 5 μg of purified FIP3 were incubated with 50 ng of recombinant Cdk1-cyclin B complex in the presence of ATP-g-
32P for 30 min as
described (also shown is a control in which 5 μg of FIP3 was incubated without kinase or ATP). Samples were then boiled in Laemmli buffer, separated
on SDS-PAGE and examined by autoradiography. Shown is data from a typical experiment, repeated 4 times with similar results.
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Page 6 of 15Figure 5 S102D expression perturbs cytokinesis. Panel A HeLa cells on glass coverslips were transiently transfected with GFP-FIP3, or the
indicated mutants as described. After 48 h, cells were fixed and microtubules (anti-tubulin) and DNA (DAPI) stained as described. The fraction of
cells expressing each FIP3 species that were binucleate was then determined and is plotted graphically. The data shown are from a
representative experiment: in this case over 200 GFP-positive cells were counted per condition. *indicates a significant increase over control
(GFP-FIP3) cells p = 0.02, and **p < 0.05. Similar results were obtained in two other experiments of this type, but the fraction of binucleate cells
varied between experiments (e.g. the% of binucleate cells expressing GFP-FIP3-I737E varied between 16 and 33%). Panel B shows an
immunoblot from the same experiment in which equal amounts of lysate were immunoblotted with anti-GFP to show that similar levels of each
mutant were expressed. Anti-GAPDH is used as a loading control. Panel C shows the cytosol/membrane ratio of the indicated mutants in cells
synchronised in metaphase. Data from a representative experiment is shown. Panel D HeLa cells on glass coverslips were transiently transfected
with GFP-FIP3 (pseudo-coloured green), or the indicated mutants as described. After 24 h, cells were fixed and immunostained with anti-tubulin
(pseudo-coloured red) and the distribution of cells in telophase examined. Shown are cells in early or late telophase. Data from a representative
experiment, repeated 5 times are shown. Note that the categorisation of these images into ‘early’ or ‘late’ telophase is dictated by the
appearance of FIP3 (see [11] for details) which is highly dynamic in telophase, moving from a characteristic perientrosomal localisation into the
intercellular bridge region as cells move from early to late telophase. Panel E HeLa cells expressing HA-FIP3 or HA-FIP3-4A were analysed by
immunofluoresence microscopy using monoclonal anti-HA in telophase to reveal the localisation of epitope-tagged FIP3. Shown are typical
images of cells in early or late telophase, pseudo-coloured green. Data from a representative experiment, repeated 3 times are shown.
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Page 7 of 15distribution of function. One explanation for this is that
perhaps other, as yet unstudied, sites may be either more
important or act cooperatively with those described here.
Returning to our initial hypothesis that phosphorylation
may represent a potential mechanism for the regulation
of FIP3 cytosol/membrane ratio in the cell cycle, we used
Figure 6 Distribution of phosphomimetic mutants of FIP3 and their effect on transferrin uptake in interphase cells. HeLa cells on glass
coverslips were transiently transfected with GFP-FIP3 or the indicated mutants as described in Methods. 48 h later, cells were incubated for two
hours in serum free D-MEM, transferred to media supplemented with 1 μg/ml human transferrin conjugated to Texas Red and incubated at 37°C
for 30 minutes. Cells were fixed and the distribution of GFP-FIP3 (pseudo-coloured green) and Tf (pseudo-coloured red) analysed by confocal
microscopy. Merged images were generated using the Zeiss confocal software. Shown are representative images for each mutant. Over 50 cells
were analysed for each mutant at each condition, and each experiment was performed in triplicate.
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Page 8 of 15a phospho-protein affinity column to selectively bind
phosphorylated proteins from HeLa extracts, isolated
from prophase/metaphase arrested cells or from cells in
telophase (Figure 7A). The phospho-affinity column
retained FIP3 from prophase/metaphase arrested cells,
but the extent of FIP3 binding was considerably reduced
in telophase extracts. Such data suggest that FIP3 is
phosphorylated in early stages of the cell cycle (meta-
phase) and dephosphorylated in later stages (telophase).
As this corresponds to a movement of FIP3 from largely
cytosolic (metaphase) to membrane associated (telo-
phase), we tested this hypothesis by examining the mem-
brane/cytosol distribution of FIP3 in metaphase
homogenates, treated with or without phosphatase, and
then subsequently separated into membrane and cytosol
fractions. As revealed in Figure 7B, dephosphorylation of
FIP3 consistently resulted in more FIP3 distributing to
the membrane fraction. Such data support the hypothesis
that FIP3 is a phosphoprotein. As a control for these
experiments, we examined the distribution of another
Rab11 effector, Rab Coupling Protein (RCP)/FIP1. The
distribution of RCP/FIP1 between membrane and cytoso-
lic fractions was not altered during the cell cycle (see
Figure 1). Similarly, the levels of phosphorylated RCP/
FIP1 did not differ between metaphase and telophase
(Figure 7). Such data suggest that the cell cycle-induced
changes in localization and phosphorylation are specific
to FIP3. Although a modest change in membrane/cytosol
ratio was observed for over-expressed GFP-FIP3-S102D,
this did not approach the magnitude reported here for
GFP-FIP3 (wild-type). Nonetheless, these data strongly
support the notion that the cytosol to membrane translo-
cation of FIP3 occurs concomitantly with dephosphoryla-
tion. In an attempt to determine whether this was a
direct effect, we incubated recombinant FIP3 (pre-treated
with alkaline phosphatase) with either artificial lipid vesi-
cles or membranes from HeLa cells. We could not detect
any direct interaction under these conditions (Figure 7C).
Discussion
FIP3 is a Rab11 binding protein essential for the com-
pletion of abscission [8,9,20]. Previous work from our
group and others has shown that FIP3 exhibits consider-
able changes in subcellular distribution throughout the
cell cycle. Here, we have investigated the potential role
of phosphorylation as a mechanism to control FIP3 dis-
tribution. We have shown that FIP3 is a cell cycle-regu-
lated phosphoprotein (Figure 7), and that levels of
phosphorylation of FIP3 decrease as cells move from
anaphase into telophase (Figure 7). This dephosphoryla-
tion of FIP3 is accompanied by a shift of FIP3 from a
largely cytosolic fraction to a membrane fraction (Figure
7), consistent with the observed distribution of GFP-
FIP3 reported by us and others [8,21]. Using MS
approaches we have identified four putative sites of FIP3
phosphorylation: S102, S280, S347 and S450 (Figure 1),
extending the list of potential phospho-acceptor sites
within FIP3 - see Figure 2C[14]. Of these, we show that
phosphorylation of S102 is cell cycle regulated.
S102 lies within a consensus site for proline-directed
kinases, including Cdk1 [17,22,23]. Since Cdk1 activity
is tightly regulated during the cell cycle [3,17], we tested
the hypothesis that Cdk1-cyclin B could phosphorylate
this site in vitro. Figure 4 shows that recombinant
Cdk1-cyclin B phosphorylated recombinant FIP3 in vitro
solely on S102. Consistent with Cdk1-cyclin B kinase
phosphorylating FIP3 in vivo, levels of pS102-FIP3 fall
as cells progress from anaphase into telophase (Figure
3C, D). In an attempt to determine the functional signif-
icance of this phospho-acceptor site, we generated
S102A and S102D mutants and expressed these in HeLa
cells. Expression of GFP-FIP3-S102D but not GFP-FIP3-
S102A resulted in a modest but reproducible increase in
the number of binucleate cells, consistent with a defect
in cytokinesis (Figure 5). However, this effect was signif-
icantly less than that observed upon expression of GFP-
FIP3-I737E, a Rab11-binding defective mutant [8]. The
molecular basis of the role of S-102 in cytokinesis
remains to be established (see below).
We examined the functional consequences of S > A or
S > D mutation at all of the sites identified here (S-102,
S-280, S-347 and S-450). With the exception of S102D,
over-expression of these mutants in HeLa cells had no
effect on the numbers of binucleate cells or the distribu-
tion of FIP3 in the cell cycle (not shown). Of note, we
also expressed all combinations of double, triple and
quadruple Aspartate mutants. None of these exhibited
significant increases in the numbers of binucleate cells
(compared to S102D alone). Similarly, the interphase role
of FIP3 in the spatial control of the recycling endosomal
compartment and in transferrin recycling did not appear
to be impaired by over-expression of any of the phospho-
mutants (Figure 6). One exception to this concerns GFP-
FIP3-S450A. We consistently observed that transfection
of HeLa cells with GFP-FIP3-S450A led to significant cell
death, with little, if any, immuno-reactive GFP-FIP3-
S450A observed (not shown). By contrast, GFP-FIP3-
S450D did not modulate cell growth, and its localisation
was identical to that of GFP-FIP3. Interestingly, when
double, triple or quadruple phospho-mutants were gener-
ated, any mutant containing S450A failed to express (data
not shown). Such observations suggest that this residue
may be involved in FIP3 stability, processing or folding,
but further studies will be required to determine the
basis of this.
More than 20 phospho-acceptor sites on FIP3 (and its
fly homologue Nuclear Fallout) have recently been iden-
tified [14]. Phosphorylation of Nuf by IKK-ε has been
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Page 9 of 15shown to regulate the trafficking of Rab11-positive recy-
cling endosomal-derived vesicles into and out of the fly
bristle tip by coordinating its interaction with dynein
[14,24]. Mutation of S-488, 538, 647 and 648 to A (HA-
FIP3-4[A]) was also shown to modulate the ability of
IKK-ε to control recycling endosome directionality [14].
Figure 7 Cytosol to membrane translocation of FIP3 occurs concomitantly with dephosphorylation. Panel A Synchronized HeLa cells at
prophase/metaphase (0 min) or telophase (70 min) were lysed in the presence of phosphatase inhibitors as described in methods. The lysates
were then passed over a Phospho-Protein purification column (Qiagen). The column was washed to remove non-phosphorylated material, and
phosphoproteins eluted. The amount of FIP3 and RCP were then analyzed by immunoblotting equal amounts of lysate or eluate, as shown. Data
from a representative experiment is shown, repeated with similar results. Panel B. Synchronized HeLa cells were harvested immediately after
release from nocodazole block. Half of the cell lysates were treated with alkaline phosphatase before fractionation of the lysates into cytosolic
and membrane fractions. The levels of FIP3, TfR and RCP in all fractions were then analyzed by immunoblotting. Data from a representative
experiment is shown, repeated three times. Panel C. Density gradient analysis of FIP3 association with HeLa membranes. Phosphatase-treated,
recombinant FIP3 was incubated with either HeLa membranes or protein-free liposomes. These membranes (or vesicles) were then floated up
through an Optiprep gradient. Fractions were collected and the distribution of proteins within the gradients was assayed by immunoblotting
using the antibodies shown. The FIP3 sample incubated with HeLa membranes was blotted for Rab5, as a marker for endocytic membranes. The
bottom and top of the Optiprep density gradient is marked. Data from a typical experiment, repeated with two different preparations of lipid
vesicles and HeLa membranes is shown.
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these sites may control the interaction of FIP3-positive
vesicles with the microtubule network and thus modu-
late the function and/or distribution of FIP3 in the cell
cycle. However, over-expression of HA-FIP3 (wild-type)
or HA-FIP3-[4A] did not affect cytokinesis as revealed
by quantification of the levels of binucleate cells (Addi-
tional file 1: Figure S1). Similarly, the membrane/cytosol
ratio of HA-FIP3 (wild-type) and HA-FIP3-[4A] in
metaphase were similar (Additional file 1: Figure S1),
consistent with these mutations not exerting a signifi-
cant effect on the interaction of FIP3 with membranes.
Similarly, the distribution of this mutant during the cell
cycle was indistinguishable from the HA-tagged wild-
type FIP3 (Figure 5).
FIP3 is a cell cycle regulated phosphoprotein
The identification of a range of phospho-acceptor sites
within FIP3 begs the question of the functional role of
these sites. Given the significant redistribution of GFP-
tagged FIP3 from cytosol to membranes (Figure 1) dur-
ing the cell cycle and our observation that S-102 is
dephosphorylated during progression from metaphase to
telophase (Figure 3), we further explored whether phos-
phorylation of FIP3 is modulated during the cell cycle.
To test this, we used a phospho-protein affinity column
to selectively bind phosphorylated proteins from HeLa
extracts, isolated from prophase/metaphase arrested
cells or from cells in telophase (Figure 7A). The phos-
pho-affinity column retained FIP3 from prophase/meta-
phase arrested cells, but the extent of FIP3 binding was
considerably reduced in telophase extracts. Such data
suggest that FIP3 is phosphorylated in early stages of
the cell cycle (metaphase) and dephosphorylated in later
stages (telophase). As this corresponds to a movement
of FIP3 from largely cytosolic (metaphase) to membrane
associated (telophase), we tested this hypothesis by
examining the membrane/cytosol distribution of FIP3 in
metaphase homogenates, treated with or without phos-
phatase, and then subsequently separated into mem-
brane and cytosol fractions. As revealed in Figure 7B,
dephosphorylation of FIP3 consistently resulted in more
FIP3 distributing to the membrane fraction. Such data
support the hypothesis that FIP3 is a phosphoprotein.
As a control for these experiments, we examined the
distribution of another Rab11 effector, Rab Coupling
Protein (RCP)/FIP1. The distribution of RCP/FIP1
between membrane and cytosolic fractions was not
altered during the cell cycle. Similarly, the levels of
phosphorylated RCP/FIP1 did not differ between meta-
phase and telophase. Such data suggest that the cell
cycle-induced changes in localization and phosphoryla-
tion are specific to FIP3.
These data suggest that dephosphorylation of FIP3
accompanies its redistribution from a cytosolic fraction
to a membrane fraction. Several lines of argument sug-
gest that dephosphorylation of FIP3 alone is unlikely to
be sufficient to mediate this. Firstly, we and others have
shown that FIP3 is recruited to membranes via interac-
tion with Rab11 [8,9,25]. Indeed, inspection of the data
in Figure 6 reveals that a FIP3 mutant (I737E) unable to
bind Rab11 is cytosolic [8]. Hence, the interaction with
Rab11 is likely to be the most important factor control-
ling FIP3 membrane distribution. Secondly, recombinant
FIP3 does not bind either to phospholipid vesicles or to
intracellular membranes isolated from HeLa cells (Fig-
ure 7C). Finally, neither S > D nor S > A mutants exhib-
ited altered distribution of GFP-FIP3 throughout the cell
cycle (Additional file 2: Figure 2 and data not shown).
Collectively, these data suggest that although FIP3 is a
cell cycle-regulated phosphoprotein, the consequences
of phosphorylation are not primarily to control the loca-
lisation of FIP3. This is also consistent with the location
of the phospho-sites within FIP3: all four sites studied
here are located towards the N-terminal domain of
FIP3, and are not within the coiled-coil domain which
encompasses the sites of Rab11, Arf6 and Cyk-4 interac-
tion (Figure 2C) [8,11]. It should be noted that FIP3 has
multiple other potential phospho-acceptor sites, and
over 20 such sites have been reported to be phosphory-
lated in vitro [14]. Some of these sites are located within
the coiled-coil domain, and may modulate the interac-
tion of FIP3 with other proteins or possibly control FIP3
homo-dimerisation. Mutation of the sites reported here
did not in our hands modulate the distribution of
dynein (not shown), nor affect the re-distribution of
recycling endosomes characteristic of FIP3 over-expres-
sion (Figure 6). Similarly, traffic of cargo into and out of
the clustered endosomes was not modulated by either
S > A or S > D mutation of these sites singly (Figure 6)
or collectively.
Conclusions
Here we have shown that FIP3 is a cell cycle regulated
phosphoprotein, and that FIP3 dephosphorylation
occurs concomitantly with the shift from largely cytoso-
lic to membrane bound observed as cells pass from
metaphase to telophase. The phospho-acceptor sites stu-
died here do not appear to control these changes. There
are several possible explanations for this. First, the sites
identified are not involved in this interaction, or that
multiple sites of de/phosphorylation are involved. Alter-
natively, it is possible that multiple mechanisms of FIP3
targeting exist: this is consistent with studies showing
that Rab11, Arf6 and Ect2 are all binding partners for
FIP3, and all may contribute to FIP3 localisation. It is
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trol all of these interactions. We favour a model in
which the membrane association of FIP3 is driven
mainly by interaction with Rab11 (consistent with other
studies) and that dephosphorylation of FIP3 may repre-
sent a distinct regulatory mechanism, perhaps involving
motor protein interactions resulting in the accumulation
of FIP3 in midbodies. Further work will be required to
resolve these models.
Methods
Antibodies and reagents
Anti-peptide antibodies were generated against a 9
amino acid synthetic peptide encompassing phospho-
S102 as the central residue, and containing an additional
C-terminal Cys residue for conjugation to keyhole lim-
pet hemocyanin [NH2-GQLA(p)SPDAPC-COOH]. Con-
jugation of the peptide and immunisation of rabbits was
performed by the Scottish Blood Transfusion Service.
Phospho-selective antibodies were purified by a two step
method. Total IgG was purified using a Protein-A
sepharose column and dialysed extensively against PBS
(137 mM NaCl, 2.7 mM KCl, 8.1 mM NaH2P04,1 . 7 6
mM KH2P04, pH7.4). The phospho-specific antibodies
were then affinity-purified over a column of the phos-
pho-peptide coupled to Sulpho-link resin (Peirce), eluted
in 20 mM Glycine pH 2.5, dialysed against PBS and
snap-frozen prior to use.
Mouse anti-GAPDH and rabbit anti-GFP antibodies
were purchased from Abcam plc. (UK). Rat anti-tubulin,
clone YL1/2 antibody was purchased from Millipore
(UK) Ltd. Alexa Fluor
® 568 goat anti-rat IgG was pur-
chased from Invitrogen (UK) Ltd. Anti-FIP3, Rab11, and
other antibodies were as described in [7-9].
Lipofectamine™ 2000, Texas-red transferrin, Myelin
basic protein (MBP) and DAPI (4, 6-diamidino-2-phe-
nyindole dilactate) were from Invitrogen (UK). Cyclin B-
CDK1 kinase was purchased from Millipore (UK) Ltd.
Adenosine 5’ triphosphate, ATP, (g-32P) 3000 Ci/mmol
(10 mCi/ml) was from PerkinElmer Life and Analytical
S c i e n c e s ,I t a l y .P h o s p h o - p r o tein affinity columns were
from Qiagen.
Recombinant FIP3 production
Full-length human FIP3 was tagged with an N-terminal 6-
His tag followed by a TEV cleavage site by sub-cloning
into the baculovirus transfer vector pVL1392. Co-transfec-
tion and amplification of recombinant baculoviruses was
done by using BacPAK transfection reagents (BD Clon-
tech, Palo Alto, CA), following the manufacturer’s proto-
cols. In brief, 1 × 10
6 Sf9 cells were seeded into a 6-well
plate and Bacfectin-DNA mixture was added drop-wise.
After 5 days the P1 viral stock was harvested and further
amplified to P2 and P3 stages. For protein production, 1 l
of Sf9 cells at 2 million cells/ml were infected with 2 ml of
P3 viral stock (approximate multiplicity of infection: 0.5)
and harvested after 65 h. Cells were lysed in 50 mM Tris
buffer (pH 7.5) containing 300 mM NaCl, and the cleared
lysate was loaded onto a Ni-NTA column. Eluted 6His-
FIP3 was further purified using a S75 size exclusion chro-
matography column. Yields were typically 3-5 mg/l with
an estimated purity of > 85%.
Cell culture, transfection and imaging
Human cervical carcinoma HeLa cells were cultured in
Dulbecco’s Modified Eagle Medium (D-MEM) with 4.5
g/L glucose, supplemented with 10% (v/v) Foetal Calf
Serum EU, 2 mM Glutamine, 100 Units/ml Penicillin and
100 μg/ml Streptomycin. HeLa cells stably expressing
GFP-FIP3 were maintained in the same media containing
100 μg/ml Hygromycin B (Sigma-Aldrich Company Ltd.,
UK). Cells were transfected with plasmid DNA, using
Lipofectamine™ 2000 following the manufacturer’s
instructions in antibiotic free media. The antibiotic-free
growth media was changed 4-6 h after transfection and
replaced with normal growth media. Cells were processed
for transgene expression 24 to 72 h post-transfection. For
time-lapse microscopy, cells were grown on collagen-
coated coverslips and 24 h later viewed using a 20× lens
in an environmental chamber at 5% CO2, 37°C.
Cell synchronisation
HeLa cells were synchronized using thymidine/nocoda-
zole block as described in [11]. HeLa cells were incu-
bated for 16 h in the presence of 5 mM thymidine, then
washed and incubated in fresh serum-supplemented
media. After 8 h, 100 ng/ml of nocodazole was added
and cells were incubated for another 16 h. Cells arrested
in metaphase were then dislodged by gently tapping the
side of the dish. Cells were collected and released from
nocodazole mitotic block by washing in serum-supple-
mented media. After release from thymidine/nocodazole
block, HeLa cells reach late telophase in approximately
3 h (see [11]).
Immunofluorescence and transferrin trafficking
Cells were grown on 12-well plates containing ethanol-
sterilised 13 mm diameter glass coverslips for 24 h prior
to processing. Cells were fixed with 4% (w/v) r-formal-
dehyde (4% r-formaldehyde, 1 mM CaCl2, 1 mM MgCl2
in PBS) and incubated at room temperature for 20 min.
r-formaldehyde was quenched in 30 mM NH4Cl and
after washing in PBS, cells were permeabilised with 0.1%
(v/v) Triton (in PBS) for 4 min. Cells were blocked in
immunofluorescence (IF) buffer (PBS containing 0.2%
(w/v) fish skin gelatin and 0.1% (v/v) goat serum) then
incubated with primary antibody for 1 h at room tem-
perature. After washing, cells were further incubated for
Collins et al. BMC Cell Biology 2012, 13:4
http://www.biomedcentral.com/1471-2121/13/4
Page 12 of 151 h with secondary antibodies diluted in IF buffer. For
nuclear staining, DAPI was added to wash buffers as
described [8]. Coverslips were mounted using Shandon
Immu-Mount (Thermo Fisher Scientific). Coverslips
were analysed using a 63X Zeiss oil immersion objective,
on a Zeiss confocal microscope (Carl Zeiss, Germany)
equipped with a Zeiss LSM5 Pascal instrument. An
argon laser was used to excite 488 nm Alexa Fluor
®
Dyes and GFP fusion proteins. Helium neon lasers were
used to excite 568 nm Alexa Fluor
® Dyes. Zeiss Pascal
software was used to collect images, which were saved
as.mdb files.
For transferrin uptake assays, transfected cells were
incubated for two hours in serum free D-MEM, then
transferred to media supplemented with human trans-
ferrin conjugated to Texas Red (1 μg / m l )a t3 7 ° Ci n5 %
(v/v) CO2 for 5 - 30 mins (see figure legends). Following
incubation, cells were fixed with 4% r-formaldehyde as
above and mounted onto glass slides for imaging [7].
GFP-FIP3 mutant construction
GFP-FIP3 was that described in [8]. Mutations (S > A or
S > D) were generated using a QuickChange kit (Strata-
gene) according to the manufacturer’s instructions using
Advantage
® GC Genomic LA Polymerase from Clontech
(France). Some of the mutants were made by Dundee
Cell Products Ltd. (Dundee, Scotland). Mutants were
fully sequenced on both strands. The 4A-mutant of
FIP3 was as described in [14].
Subcellular fractionation and immunoblotting
To isolate cytosol and membrane fractions, synchronized
mitotic HeLa cells were resuspended in 5 mM Hepes, pH
7.4 buffer and incubated for 10 minutes. Cells were then
lysed using glass-glass homogenizer. Nuclei and debris
were then sedimented at 3, 000 × g. The supernatant was
then further centrifuged for 1.5 hours at 100, 000 × g to
generate a cytosol fraction (supernatant) and a membrane
fraction (pellet). The pellet was extracted with 20 mM
Hepes, pH 7.4, containing 100 mM NaCl and 1% (v/v) Tri-
ton X-100. The solubilized membrane fraction (superna-
tant) was then sedimented for 1.5 hours at 100, 000 × g.
To determine the relative levels of FIP3 in the cytosol and
membrane fractions, 60 μg of fraction was separated on
SDS/PAGE and immunoblotted with anti-FIP3, anti-TfR
and anti-FIP1/RCP antibodies [8,26,27]. TfR, an integral
membrane protein, was used as a control for the purity of
fractions. FIP1/RCP, another member of Rab11-FIP family
of proteins that is not required for cytokinesis, was used as
negative control [8].
To isolate phosphorylated protein fractions, HeLa cells
were lysed in 20 mM Tris HCl, pH7.4, containing
100 mM NaCl and 1% (v/v) Triton X-100. Lysates were
then applied to PhosphoProtein purification column
(Qiagen) and phosphorylated proteins purified according
to manufacturer’s instructions. Phospho-protein frac-
tions were then separated by SDS/PAGE and immuno-
blotted with anti-FIP3 and anti-FIP1/RCP antibodies.
Density gradient analysis of FIP3 association with
membranes
HeLa membranes were prepared by passing HeLa cells
through a ball-bearing homogeniser with a 14 μm clear-
ance in 20 mM Hepes, 250 mM sucrose, 2.5 mM EDTA
pH7.4 (HES buffer). After a 5 min centrifugation at 3000 ×
g to pellet nuclei, total membranes were sedimented at
100, 000 ×g for 30 min, and re-suspended in HES buffer at
around 2 mg/ml. Protein-free liposomes were prepared
exactly as described in [28]. For the experiment shown, 30
μl of HeLa membranes, or 30 μl of protein-free liposomes
were incubated with 10 μM recombinant FIP3 (previously
incubated with alkaline phosphatase) on ice for 90 min
with occasional mixing. After this, samples were mixed
with OptiPrep such that the final concentration was 40%
(v/v) then overlaid in a centrifuge tube with 20% and 5%
(v/v) layers. Samples were centrifuged for 4 h at 4°C at 85,
000 ×g and fractions were collected from the bottom of
the tube, protein precipitated by tri-chloroacetic acid and
analysed by SDS-PAGE and immunoblotting.
In vitro phosphorylation assay
Reactions were set up in screw-capped micro-centrifuge
tubes, as follows: 50 ng recombinant Cdk1/cyclin B was
added to kinase assay buffer (50 mM Hepes pH 7.5,
10 mM MgCl2,2m MM n C l 2, 0.2 mM DTT and 50 μM
ATP.Mg
2+) to produce a final volume of 50 μl, followed
by 2 μgo r5μg recombinant FIP3. 2 μgM B Pw a su s e d
as a positive control for kinase activity. To start the
reaction, 6 μCi ATP-g-32P was added to each tube and
reactions were incubated in a water bath at 30°C for
30 min. 20 μl of Laemmli sample buffer (with 80 mM
DTT) was added to each tube to stop the reaction. Sam-
ples were separated by SDS-PAGE, dried and exposed to
Kodak X-ray film in a cassette with no intensifying
screen at room temperature for 24 to 96 h.
Identification of phospho-sites: In vivo phospho-site
identification
Synchronized HeLa cell lysates from twenty 10-cm plates
were harvested at prophase/metaphase (0 min after
release from the nocodazole block). Cells were lysed in
the presence of 1% Triton X-100 and phosphatase inhibi-
tors, then incubated overnight with either 20 μg/ml lysate
of affinity-purified goat anti-FIP3 antibodies or 20 μg/ml
lysate of purified nonspecific goat IgG, followed by addi-
tion of 100 μlo fp r o t e i nA - s e p h a r o s ep e r1m lo fl y s a t e .
Beads were then washed, eluted with 1% SDS and sepa-
rated on a 7-14% gradient acrylamide gel. The resulting
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Gel bands were cut and in-gel digested using trypsin and
proteinase K. Peptides were extracted from the gel pieces
with 0.1% TFA/60% acetonitrile and lyophilized. Dried
peptide samples from each gel band were rehydrated and
loaded onto a microcapillary column (100 mm inner dia-
meter fused silica) packed with 15 cm Aqua C18 reverse-
phase material and then placed in-line with an LTQ lin-
ear trap mass spectrometer. Peptides were eluted with 2
h mobile gradient of acetonitrile/0.1% formic acid. Tan-
dem mass spectra were analyzed using Sequest using a
human-mouse-rat database concatenated to a rando-
mized human-mouse-rat database. DTASelect was used
to reassemble identified peptides into proteins.
Identification of sites of recombinant FIP3
phosphorylated in vitro
In vitro phosphorylation assays were performed on Bacu-
lovirus-expressed recombinant FIP3 using recombinant
Cdk1/cyclin B as described above with the following
modifications: 200 ng recombinant kinase (or buffer for
control reactions) was incubated in 0.1 ml of kinase assay
buffer supplemented with 100 μMA T P . M g
2+.5 0μg
recombinant FIP3 was added to initiate the reaction
which was then incubated at 30°C for 60 min. Protein
was TCA precipitated, centrifuged at 23, 880 g 15 min-
utes at 4°C and separated via SDS-PAGE using
NuPAGE
® reagents (Invitrogen (UK) Ltd.). The gel was
stained with Brilliant Blue G-Colloidal Concentrate
(Sigma-Aldrich Ltd., UK). FIP3 was excised from the gel
and the phosphorylation site mapping of kinase phos-
phorylated FIP3 was carried out commercially by the Fin-
gerPrints Proteomic Facility at the University of Dundee
(UK). This service uses a technique known as parent ion
scanning (also known as Parents of -79) to detect phos-
phorylated peptides in conjunction with the generation
of tandem MS data to identify the protein(s) in the solu-
tion to determine the sites of phosphorylation in the
protein.
Additional material
Additional file 1: Figure S1. HA-FIP3-4A does not modulate cytokinesis.
HeLa cells on glass coverslips were transiently transfected with HA-FIP3,
or HA-FIP3-4A as described. After 48 h, cells were fixed and cells
expressing HA-tagged FIP3 identified by immunostaining as described. In
parallel, microtubules (anti-tubulin) and DNA (DAPI) were also stained.
The fraction of cells expressing each FIP3 species that were binucleate
was then determined and is plotted graphically in panel A. The data
shown are from a representative experiment: over 200 GFP-positive cells
were counted per condition. The experiment was repeated three times
with similar results. Inset shows an anti-HA immunoblot of cell lysates to
verify broadly similar expression levels of each construct.
Additional file 2: Figure S2. GFP-FIP3 distribution in early and late
telophase is not modulated by phosphorylation of S280, S347 or Ser 450.
HeLa cells on glass coverslips were transiently transfected with GFP-FIP3
(pseudo-coloured green), or the indicated mutants as described. After 24
h, cells were fixed and immunostained with anti-tubulin (pseudo-
coloured red) and the distribution of cells in telophase examined. Shown
are cells in early or late telophase (cf. Figure 5). Data from a
representative experiment, repeated 5 times are shown.
Abbreviations
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